Atherosclerotic cardiovascular disease

There are 1,197 papers on atherosclerotic cardiovascular disease in aging research: 83 trials and 683 observational studies in people, 7 in animals, 1 in cells, 382 reviews. The newest story, Nov 19, 2026: “Higher urine ketone scores linked to lower artery disease risk”.

Disease

1,197 papers study it520 more mention it484 findings

410 new papers in 30 daysSee all 1,717 papers on atherosclerotic cardiovascular disease

“Upon assessing the (ASCVD) risk class distribution between the two groups, a significant difference was noted at the end of the trial (P = 0.004).”
Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular riskScientific reports2025doi:10.1038/s41598-025-09783-5
  • Human trial83
  • Humans683
  • Animals7
  • Cells1
  • In silico30

Interventions

17

Statins

downin humans6no changein humans1HR 0.76–0.94

6 studies
  1. Statins were not clearly linked with atherosclerotic cardiovascular disease in humans (without type 2 diabetes, aged 75-84 years) (HR 0.94 (95% CI 0.86 to 1.04)).

    “statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality”

    Humanswithout type 2 diabetes, aged 75-84 years

    Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

    BMJ (Clinical research ed.)

  2. Statins are linked with lower atherosclerotic cardiovascular disease in humans (participants with type 2 diabetes) (HR 0.76 (95% CI 0.65 to 0.89)).

    “the hazard ratio of statin use in 75-84 year olds was 0.76 (0.65 to 0.89) for atherosclerotic CVD”

    Humansparticipants with type 2 diabetes

    Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

    BMJ (Clinical research ed.)

  3. Statins prevent atherosclerotic cardiovascular disease in humans.

    “Statins remain the mainstay of pharmacotherapy for reducing concentrations of total cholesterol and low-density lipoproteins, as well as for preventing atherosclerotic cardiovascular disease.”

    Review

    Statins and safety: an evidence-based assessment of common beliefs about adverse effects with a focus on endocrinology practice

    Axis of endocrinology

  4. Statins prevent atherosclerotic cardiovascular disease in individuals from high-risk families with an elevated CAC score.

    “In individuals from high-risk families with an elevated CAC score, ASCVD events can be prevented when treated with statins and aspirin.”

    Reviewin individuals from high-risk families with an elevated CAC score

    Premature atherosclerosis: An analysis over 39 years in the Netherlands. Implications for young individuals in high-risk families

    Atherosclerosis

  5. Statins protect against atherosclerotic cardiovascular disease in humans (secondary prevention).

    “support treatment in secondary prevention of atherosclerotic cardiovascular disease (ASCVD)”

    Reviewsecondary prevention

    Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients

    Current atherosclerosis reports

  6. Statins prevent atherosclerotic cardiovascular disease in humans (primary prevention).

    “sensible use of statin therapy to prevent a first and potentially devastating ASCVD event is critically important to ensure a healthy aging population.”

    Reviewprimary prevention

    Primary Prevention With Statins in the Elderly

    Journal of the American College of Cardiology

  7. Statins prevent atherosclerotic cardiovascular disease in humans (primary and secondary prevention).

    “Current international and local guidelines recommend statin therapy for the primary and secondary prevention of ASCVD.”

    Reviewprimary and secondary prevention

    Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective

    Singapore medical journal

More on Statins

Sleep

downin humans2

2 studies
  1. Sleep is linked with less atherosclerotic cardiovascular disease in humans.

    “Healthy sleep and physical activity were protective across outcomes.”

    Humans13 yearsn = 468,266

    Risk factors for atherosclerosis diverge across vascular beds

    American journal of preventive cardiology

  2. Sleep is linked with less atherosclerotic cardiovascular disease in humans (UK Biobank participants).

    “Healthy sleep and physical activity were protective.”

    HumansUK Biobank participantsn = 468,266

    Multidomain Risk Profiles and Disease Progression Across Atherosclerotic Vascular Beds

    AHA Scientific Sessions 2025 abstract

More on Sleep

Physical activity

downin humans2

2 studies
  1. Physical activity is linked with less atherosclerotic cardiovascular disease in humans.

    “Healthy sleep and physical activity were protective across outcomes.”

    Humans13 yearsn = 468,266

    Risk factors for atherosclerosis diverge across vascular beds

    American journal of preventive cardiology

  2. Physical activity is linked with less atherosclerotic cardiovascular disease in humans (UK Biobank participants).

    “Healthy sleep and physical activity were protective.”

    HumansUK Biobank participantsn = 468,266

    Multidomain Risk Profiles and Disease Progression Across Atherosclerotic Vascular Beds

    AHA Scientific Sessions 2025 abstract

More on Physical activity

GLP-1 receptor agonists

downin humans2

2 studies
  1. GLP-1 receptor agonists protect against atherosclerotic cardiovascular disease in people with type 2 diabetes.

    “they protect people with T2D against atherosclerotic cardiovascular disease”

    Reviewin people with type 2 diabetes

    A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists

    Revue medicale de Liege

  2. GLP-1 receptor agonists protect against atherosclerotic cardiovascular disease in humans.

    “but also protect against atherosclerotic cardiovascular disease”

    Review

    A new era for glucagon-like peptide-1 receptor agonists

    Revue medicale de Liege

More on GLP-1 receptor agonists

Saturated fat intake

no changein humans1HR 1

1 study
  1. Saturated fat intake was not clearly linked with atherosclerotic cardiovascular disease in humans (Bottom 3 quartiles of PGSLDL; without prevalent ASCVD) (HR 1.00, 95% CI 0.89–1.12).

    “no association was observed among those in the bottom 3 quartiles (HR: 1.00; 95% CI: 0.89-1.12)”

    HumansBottom 3 quartiles of PGSLDL; without prevalent ASCVD5% isocaloric increaseMedian follow-up: 10 years

    Saturated fat’s cholesterol link may vary with genetic risk

    JACC. Advances

More on Saturated fat intake

Hormone replacement therapy

no changein humans1HR 0.98

1 study
  1. Hormone replacement therapy was not clearly linked with atherosclerotic cardiovascular disease in humans (Free of baseline ASCVD, VTE, and cancer; initiation compared with non-initiation) (Adjusted HR 0.98, 95% CI 0.93–1.04).

    “contemporary HRT was not associated with increased risk of VTE, ASCVD, or premature mortality”

    HumansFree of baseline ASCVD, VTE, and cancer; initiation compared with non-initiationPredominantly contemporary oral and transdermal formulationsMean follow-up 12 years; up to 23 yearsfemalesn = 52,330

    Hormone therapy not linked to higher heart risk in 52,330 women

    AHA Scientific Sessions 2026 abstract

More on Hormone replacement therapy

PCSK9-neutralizing monoclonal antibodies

downin reviews1

1 study
  1. PCSK9-neutralizing monoclonal antibodies decrease atherosclerotic cardiovascular disease.

    “Monoclonal antibodies that neutralize circulating PCSK9 have demonstrated the utility of PCSK9 inhibition for reducing LDL-C and ASCVD.”

    Review

    In-vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9

    Current atherosclerosis reports

More on PCSK9-neutralizing monoclonal antibodies

Pelacarsen

no changein humans1

1 study
  1. Pelacarsen showed no clear effect on atherosclerotic cardiovascular disease in humans (phase 3 Lp(a)HORIZON trial).

    “topline results from the phase 3 Lp(a)HORIZON trial showed that pelacarsen, despite lowering Lp(a), did not reduce the primary composite cardiovascular endpoint.”

    Reviewphase 3 Lp(a)HORIZON trial

    Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications

    Journal of cardiovascular pharmacology

More on Pelacarsen

Fatty liver

no changein humans1HR 1.39

1 study
  1. Fatty liver was not clearly linked with atherosclerotic cardiovascular disease in humans after further adjustment for apolipoprotein B (HR 1.39, 95% CI 0.91-2.13).

    “The CVD association was attenuated to non-significance after further adjustment for apoB (HR 1.39, 95% CI 0.91-2.13, p = 0.134).”

    Humansafter further adjustment for apolipoprotein B

    Ultrasound-detected fatty liver in young adults and long-term risk of atherosclerotic cardiovascular disease: The Young Finns Study

    Atherosclerosis

More on Fatty liver

Fenofibrate

no changein humans1

1 study
  1. Fenofibrate was not clearly linked with atherosclerotic cardiovascular disease in humans (statin-treated individuals with TRL-C < median).

    “but not in those with TRL-C < median after matching”

    Humansstatin-treated individuals with TRL-C < medianmean follow-up of 87 months

    Fenofibrate plus statin and ASCVD risk by triglyceride-rich lipoprotein cholesterol in 70,000 patients

    Journal of lipid research

More on Fenofibrate

All 17

Effects

7

Disability-adjusted life years

downin humans1−42% decrease

1 study
  1. Atherosclerotic cardiovascular disease is linked with lower disability-adjusted life years in humans (atherosclerotic CVD) (41.5% decrease).

    “primarily driven by improvements in atherosclerotic CVD (41.5% decrease)”

    Humansatherosclerotic CVD1990 to 2023

    The global cardiovascular-kidney-liver-metabolic burden from 1990 to 2023

    EClinicalMedicine

Mortality

upin humans1

1 study
  1. Atherosclerotic cardiovascular disease is linked with higher mortality in humans (2019 to 2021) (APC 6.99% (741.3 to 841.5 per 100,000)).

    “the AAMR rose from 741.3 in 2019 to 841.5 in 2021, yielding an APC of 6.99%.”

    Humans2019 to 2021

    Rising atherosclerotic cardiovascular disease-related mortality among older adults in the United States: a 22-year retrospective cohort study using the CDC WONDER database

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese

Incident CHIP

no changein humans1

1 study
  1. Atherosclerotic cardiovascular disease was not clearly linked with incident CHIP in humans.

    “while ASCVD and other traditional ASCVD risk factors do not exhibit such associations.”

    Humansblood21 yearsn = 4,187

    Long-term longitudinal analysis of 4,187 participants reveals insights into determinants of clonal hematopoiesis

    Nature communications

Clonal hematopoiesis of indeterminate potential

no changein humans1

1 study
  1. Atherosclerotic cardiovascular disease was not clearly linked with clonal hematopoiesis of indeterminate potential in humans.

    “ASCVD and other traditional risk factors for ASCVD did not exhibit such associations”

    Humansn = 4,187

    Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis

    medRxiv : the preprint server for health sciencesPreprint

More on Clonal hematopoiesis of indeterminate potential

Health-related quality of life

downin humans1

1 study
  1. Atherosclerotic cardiovascular disease is linked with lower health-related quality of life in humans (β -0.10, 95% CI [-0.10, -0.09]).

    “Overall, ASCVD was associated with a substantial decrement in HALex (−0.10, [−0.10, −0.09]).”

    Humansn = 155,130

    Atherosclerotic Cardiovascular Disease and Health-Related Quality of Life Among Adults in the United States: National Health Interview Survey 2013-2017

    medRxivPreprint

Angiogenesis

downin humans1

1 study
  1. Atherosclerotic cardiovascular disease is linked with worse angiogenesis in a severity-dependent manner.

    “ASCVD impaired the colony forming capacity and the angiogenic properties of ECFC in a severity-dependent manner.”

    Humansin a severity-dependent manner

    Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD)

    International journal of molecular sciences

More on Angiogenesis

Circulating progenitor cells

upin humans1

1 study
  1. Atherosclerotic cardiovascular disease is linked with higher circulating progenitor cells in ASCVD patients.

    “Despite an increased number of circulating precursors in ASCVD patients, ASCVD impaired the colony forming capacity and the angiogenic properties of ECFC in a severity-dependent manner.”

    Humansin ASCVD patients

    Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD)

    International journal of molecular sciences

More on Circulating progenitor cells

Upstream

24

Body mass index

mediatesin humans1no changein humans1

2 studies
  1. Body mass index is linked with atherosclerotic cardiovascular disease in humans (mediating DI-GM and ASCVD association) (11.51% (95% CI: 2.54%-54.1%, P = 0.016)).

    “BMI mediated 11.51% of the association between DI-GM and ASCVD (95% CI: 2.54%-54.1%, P = 0.016)”

    Humansmediating DI-GM and ASCVD association

    Association between the dietary index for gut microbiota and atherosclerotic cardiovascular disease risk among US elderly adults: a cross‑sectional study

    Nutrition journal

  2. Body mass index was not clearly linked with atherosclerotic cardiovascular disease in humans (Shanghai community residents; prevalent disease).

    “whereas high BMI was not associated.”

    HumansShanghai community residents; prevalent diseasen = 3,950

    Abdominal obesity is strongly associated with Cardiovascular Disease and its Risk Factors in Elderly and very Elderly Community-dwelling Chinese

    Scientific reports

More on Body mass index

Metabolic syndrome

mediatesin humans1RR 1.29

1 study
  1. Metabolic syndrome is linked with atherosclerotic cardiovascular disease in humans (63.4% mediated; indirect RR 1.29, 95% CI 1.13–1.48).

    “with 63.4% of the association mediated through midlife MetS (indirect risk ratio: 1.29; 95% CI: 1.13-1.48).”

    HumansMediation of the association between young-adulthood insulin resistance and later-life ASCVDMetabolic syndrome assessed at year 20; ASCVD events through year 35n = 3,622

    Young-adult insulin resistance linked to cardiovascular risk

    JACC. Advances

More on Metabolic syndrome

Lipoprotein

no changein humans1HR 1.04

1 study
  1. Lipoprotein was not clearly linked with atherosclerotic cardiovascular disease in humans (MESA; elevated versus lower Lp(a), both without carotid plaque; similar findings in ARIC) (HR 1.04, 95% CI 0.73–1.48; absolute risk 3.86 events per 1000 person-years in MESA).

    “there was no significantly increased ASCVD risk (HR 1.04, 0.73-1.48 in MESA)”

    HumansMESA; elevated versus lower Lp(a), both without carotid plaque; similar findings in ARIC10 yearsn = 5,181

    Neck artery scans may help refine artery disease risk estimates

    AHA Scientific Sessions 2026 abstract

More on Lipoprotein

CCN1

mediatesin humans1

1 study
  1. CCN1 is linked with atherosclerotic cardiovascular disease in humans (mediation of the lipoprotein(a) association).

    “CCN1 carried one of the largest causal effects and the strongest mediation of the Lp(a)-ASCVD association”

    Humansmediation of the lipoprotein(a) association

    Genetic analysis links a blood fat particle to 60 proteins

    AHA Scientific Sessions 2026 abstract

More on CCN1

Gestational diabetes mellitus

no changein humans1

1 study
  1. Gestational diabetes mellitus was not clearly linked with atherosclerotic cardiovascular disease in humans (Pregnancy-evidence cohort; APO subtype analysis).

    “Gestational diabetes showed no clear association with ASCVD.”

    HumansPregnancy-evidence cohort; APO subtype analysisfemales

    Race and Ethnicity Differences in ASCVD Risk After Adverse Pregnancy Outcomes

    AHA Scientific Sessions 2026 abstract

More on Gestational diabetes mellitus

Plasma atherosclerosis index

mediatesin humans1

1 study
  1. Plasma atherosclerosis index is linked with atherosclerotic cardiovascular disease in humans (flavonoid intake to ASCVD risk) (11.3% proportion mediated).

    “Mediation analysis suggested a small indirect effect through AIP, with an estimated proportion mediated of 11.3%.”

    Humansflavonoid intake to ASCVD risk

    Total Flavonoid Intake, Plasma atherosclerosis index, and Risk of Incident ASCVD: A Prospective Cohort Study from the UK Biobank

    Research SquarePreprint

More on Plasma atherosclerosis index

IL-6

mediatesin humans1

1 study
  1. IL-6 is linked with atherosclerotic cardiovascular disease in humans (Partial mediation of IL-18-related risk in ART-suppressed people with HIV).

    “Associations were specific to arterial rather than venous events, and IL-18-related risk was partly mediated through IL-6.”

    HumansPartial mediation of IL-18-related risk in ART-suppressed people with HIVplasman = 1,002

    NLRP3 Activation and Impaired TGF-β Anti-Inflammatory Pathways Predict Vascular Risk in PWH on ART

    medRxiv : the preprint server for health sciencesPreprint

More on IL-6

High-density lipoprotein cholesterol

downin humans1HR 0.95

1 study
  1. High-density lipoprotein cholesterol is linked with lower atherosclerotic cardiovascular disease in humans (apoB-HDL-C interaction test) (HR 0.95, 95% CI 0.93-0.96).

    “The apoB-HDL-C interaction was significant: HR 0.95 (95% CI: 0.93-0.96; p < 0.001), consistent across sexes.”

    HumansapoB-HDL-C interaction test10 yearsn = 293,872

    Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank

    European journal of preventive cardiology

More on High-density lipoprotein cholesterol

KDM biological age acceleration

mediatesin humans1

1 study
  1. KDM biological age acceleration is linked with atherosclerotic cardiovascular disease in humans (mediating proportion 29.8%) (29.8% mediating proportion).

    “significant mediation roles of KDM.Accel and PhenoAge.Accel in the Cu-ASCVD association, with mediating proportions of 29.8% and 43.8%, respectively.”

    Humansmediating proportion 29.8%malesn = 419

    Associations Between Welding-Related Metals and Atherosclerotic Cardiovascular Disease Risk in Male Welders: The Mediating Role of Accelerated Biological Aging

    Cardiovascular toxicology

More on KDM biological age acceleration

ASGR1

downin reviews1

1 study
  1. ASGR1 decreases atherosclerotic cardiovascular disease (by ASGR1 inhibition).

    “showing ASGR1 inhibition reduces atherosclerotic cardiovascular disease.”

    Reviewby ASGR1 inhibition

    The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease

    Biomarker research

More on ASGR1

All 24

Associations

290

Lipoprotein

upin humans39upin reviews4mixedin humans1HR 1.12–1.44

44 studies
  1. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (Primary prevention cohort; high lipoprotein(a)) (Incidence increase per 50 mg/dL higher lipoprotein(a): 2.7 per 1000 person-years (95% CI 2.2-3.2) at ages 70-79; 4.5 (3.7-5.4) at ages 80-100).

    “individuals aged 70-100 with high lipoprotein(a) had the highest absolute risk of atherosclerotic cardiovascular disease.”

    HumansPrimary prevention cohort; high lipoprotein(a)Median follow-up 12.5 yearsn = 18,322

    Lipoprotein(a) and Cardiovascular Disease in Individuals Aged 70-100 Years

    AHA Scientific Sessions 2026 abstract

  2. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (CVD-free participants; one-sample Mendelian randomization) (HR per SD 1.05, 95% CI 1.02–1.08).

    “The instrument predicted both outcomes (HR per SD genetically predicted Lp(a) 1.05 [95%CI 1.02-1.08] for ASCVD; 1.12 [1.03-1.23] for AVS)”

    HumansCVD-free participants; one-sample Mendelian randomizationper SD genetically predicted Lp(a)n = 28,949

    Genetic analysis links a blood fat particle to 60 proteins

    AHA Scientific Sessions 2026 abstract

  3. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (prior ASCVD diagnosis before admission, multivariable analysis) (OR 1.638; 95% CI 1.115–2.405).

    “elevated Lp(a) was independently associated with prior ASCVD (OR 1.638; 95% CI 1.115–2.405; p = 0.012)”

    Humansprior ASCVD diagnosis before admission, multivariable analysisn = 729

    Lipoprotein(a) levels in patients hospitalized for acute coronary syndrome according to prior statin therapy

    ESC Congress 2026 abstract

  4. Lipoprotein is associated with atherosclerotic cardiovascular disease in humans (RERI 0.60; 95% CI 0.10–1.10).

    “Additive interaction was observed for older age (RERI 0.60; 95% CI: 0.10–1.10)”

    HumansAdditive interaction between elevated lipoprotein(a) and older age; without ASCVD at baseline>105 versus ≤105 nmol/LUp to 16 yearsn = 19,495

    Excess atherosclerotic cardiovascular burden associated with elevated lipoprotein(a) across age, sex, and cardiometabolic risk factors: insights from 16-year follow-up of the HUNT Study

    ESC Congress 2026 abstract

  5. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (primary prevention cohort) (HR 1.12 to 1.18 per 50 mg/dL).

    “Hazard ratios per 50 mg/dL higher lipoprotein(a) were similar across all age groups and sexes, ranging from 1.12 to 1.18”

    Humansprimary prevention cohort

    Lipoprotein(a) and Atherosclerotic Cardiovascular Disease Among Adults Aged 20 to 100 Years

    Circulation

  6. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.23 (95% CI 1.19-1.27)).

    “highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”

    Humansn = 320,506

    Metabolic, inflammatory, and lipoprotein(a)-related risk profiling for incident ASCVD: a multi-biomarker study

    Frontiers in endocrinology

  7. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (OR 1.15, 95% CI 1.07-1.24).

    “ln(Lp(a) + 1) was independently associated with the ASCVD (OR 1.15, 95% CI 1.07-1.24)”

    Humansn = 23,654

    Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort

    Journal of clinical lipidology

  8. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (>50 vs ≤50 mg/dL) (AHR 1.36, 95% CI 1.13-1.64).

    “When dichotomized (>50 vs ≤50 mg/dL), Lp(a) was associated with ASCVD in adults aged 40 years or older (AHR range, 1.36; 95% CI, 1.13-1.64)”

    Humans>50 vs ≤50 mg/dL21.3 years

    Traditional and Emerging Lipid Markers for Cardiovascular Risk Assessment in Young vs Older Adults

    JAMA network open

  9. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR: 1.24; 95% CI: 1.09-1.41).

    “Lp(a) >50 mg/dL (HR: 1.24; 95% CI: 1.09-1.41) and CAC >0 (HR: 2.44; 95% CI: 2.14-2.77) were independently associated with ASCVD risk”

    Humansn = 11,319

    Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study

    Journal of the American College of Cardiology

  10. Lipoprotein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (Per 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization) (2% higher risk per 10 nmol/L genetically predicted Lp(a)).

    “MR showed a 2% higher ASCVD risk per 10 nmol/L genetically predicted Lp(a) (P<2×10−16).”

    HumansPer 10 nmol/L genetically predicted lipoprotein(a), assessed by Mendelian randomization

    Linear and Nonlinear Associations Between Lipoprotein(a) and the Risks of Atherosclerotic Cardiovascular Disease

    Circulation journal : official journal of the Japanese Circulation Society

All 45

More on Lipoprotein

LDL cholesterol

upin humans8downin humans1mixedin humans1downin silico1+1HR 1.17

12 studies
  1. LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans (Patients genetically tested for familial hypercholesterolemia) (HR 1.17 per 1 mmol/L increase; 95% CI 1.13–1.22).

    “LDL-C was significantly associated with the risk of future ASCVD”

    HumansPatients genetically tested for familial hypercholesterolemiaPer 1 mmol/L increase in LDL-CMean follow-up 13.9 ± 9.8 yearsn = 2,327

    Cardiovascular risk among individuals with and without a genetic mutation for familial hypercholesterolemia: A long-term study

    Journal of clinical lipidology

  2. LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans (chronic kidney disease).

    “Higher levels of LDL-C, non-HDL-C, and RC were all associated with an increased risk of ASCVD.”

    Humanschronic kidney diseasemedian follow-up of 13.81 yearsn = 27,978

    Non-HDL cholesterol and remnant cholesterol are better indicators of atherosclerotic cardiovascular disease risk than LDL cholesterol in patients with chronic kidney disease

    Atherosclerosis

  3. LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans (incident CVD in people with type 2 diabetes free of CVD).

    “which was more strongly associated with worse LDL cholesterol and HbA1c”

    Humansincident CVD in people with type 2 diabetes free of CVD

    Prediction of Atherosclerotic Cardiovascular Disease vs. Heart Failure in Type 2 Diabetes—A Post Hoc Analysis of the REWIND and ORIGIN Trials

    ADA Scientific Sessions 2025 abstract

  4. LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans.

    “associations between LDL-C and all the studied cardiovascular endpoints were relatively weak”

    Humans

    Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts

    European journal of preventive cardiology

  5. LDL cholesterol raises the risk of atherosclerotic cardiovascular disease.

    “It is well established that LDL cholesterol (LDLc) is causal for atherosclerotic cardiovascular disease (ASCVD)”

    Review

    Cholesterol goals unmet in adults entering oral drug trial

    ESC Congress 2026 abstract

  6. LDL cholesterol lowers the risk of atherosclerotic cardiovascular disease in silico (lowering to 70 mg/dL or 55 mg/dL in adults with ASCVD and diabetes) (18.0% and 23.7% relative risk reduction).

    “Predicted 3-year relative risk reductions were 18.0% and 23.7%, corresponding to 38,200 and 50,100 predicted preventable events, with LDL-C lowering to 70 mg/dL or 55 mg/dL, respectively”

    In silicolowering to 70 mg/dL or 55 mg/dL in adults with ASCVD and diabetes3 yearsn = 131

    Projected Impact of LDL-C and HbA1c Control on Cardiovascular Outcomes in ASCVD and Diabetes

    JACC. Advances

  7. LDL cholesterol raises the risk of atherosclerotic cardiovascular disease in humans.

    “LDL-C/apoB and Lp(a) are separate causative drivers of cardiovascular risk”

    Review

    LDL-C vs Lp(a): What We Know, the "Zero-LDL" Hypothesis, and Where We Stand in the PCSK9 Era

    Cardiology in review

  8. LDL cholesterol raises the risk of atherosclerotic cardiovascular disease in humans.

    “elevated low-density lipoprotein cholesterol (LDL-C) as a major modifiable risk factor”

    Review

    Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia

    Expert opinion on pharmacotherapy

  9. LDL cholesterol is associated with atherosclerotic cardiovascular disease in humans.

    “high low-density lipoprotein (LDL) cholesterol is closely associated with the onset of atherosclerotic cardiovascular disease (ASCVD)”

    Review

    Targeting Dyslipidemia in Ischemic Stroke: Pathophysiology, Clinical Evidence, and Future Perspectives

    Journal of atherosclerosis and thrombosis

  10. LDL cholesterol lowers the risk of atherosclerotic cardiovascular disease in humans (lowering LDL-C in randomized trials).

    “Randomized trial evidence firmly establishes that lowering LDL-C reduces atherosclerotic cardiovascular disease.”

    Reviewlowering LDL-C in randomized trials

    Very Low Cholesterol Non-Cardiovascular Risks: A Critical Appraisal and Framework for Individualized Management

    Lipids

All 12

More on LDL cholesterol

Statins

downin humans8upin humans1downin reviews1HR 1.26

10 studies
  1. Statins are associated with atherosclerotic cardiovascular disease in humans (active-comparator new-user design versus ezetimibe; propensity score overlap weighting) (HR 1.26, 95% CI 1.11-1.45).

    “statin initiation was associated with higher risks of ASCVD (HR 1.26, 95% CI 1.11-1.45) and AnyDem (HR 1.66, 95% CI 1.16-2.38)”

    Humansactive-comparator new-user design versus ezetimibe; propensity score overlap weightingn = 6,977

    Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart-Brain Axis

    medRxiv : the preprint server for health sciencesPreprint

  2. Statins lower the risk of atherosclerotic cardiovascular disease.

    “Statins rank among the most prevalent pharmacological treatments for the prevention and management of atherosclerotic cardiovascular disease”

    Review

    Beyond LDL-C reduction: molecular pleiotropy and emerging therapeutic roles of statins

    Naunyn-Schmiedeberg's archives of pharmacology

  3. Statins lower the risk of atherosclerotic cardiovascular disease in humans (primary and secondary prevention of cardiovascular events).

    “Low-density lipoprotein (LDL) cholesterol-lowering therapies, such as statins, have consistently demonstrated robust efficacy in the primary and secondary prevention of cardiovascular events.”

    Reviewprimary and secondary prevention of cardiovascular events

    Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

  4. Statins lower the risk of atherosclerotic cardiovascular disease in humans.

    “statins, have demonstrated that regulating liver metabolism can confer significant cardiovascular benefits.”

    Review

    Hepatic targeting in ASCVD: integrating lipid lowering and inflammation modulation from statins to gene editing

    Journal of translational medicine

  5. Statins lower the risk of atherosclerotic cardiovascular disease in humans (primary prevention).

    “Available data suggest that statin therapy in older primary prevention patients may reduce atherosclerotic cardiovascular events”

    Reviewprimary prevention

    Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society

    Journal of clinical lipidology

  6. Statins lower the risk of atherosclerotic cardiovascular disease in humans.

    “Statins delay the occurrence and development of ASCVD, and reduce the risk of cardiovascular events and death.”

    Review

    Chinese expert consensus on management of dyslipidemia in the elderly

    Zhonghua nei ke za zhi

  7. Statins lower the risk of atherosclerotic cardiovascular disease in humans (primary prevention).

    “generic statins are generally safe, effective, and inexpensive drugs serving this purpose”

    Reviewprimary prevention

    Benefits and limitations of statin use in primary cardiovascular prevention: recent advances

    Polish archives of internal medicine

  8. Statins lower the risk of atherosclerotic cardiovascular disease in humans (secondary prevention).

    “Statins (HMG-CoA reductase inhibitors) have an unequivocal benefit in reducing ASCVD risk across age groups for secondary prevention.”

    Reviewsecondary prevention

    Drug Therapy of Dyslipidemia in the Elderly

    Drugs & aging

  9. Statins lower the risk of atherosclerotic cardiovascular disease in primary and secondary prevention.

    “results of RCTs demonstrate the benefit of statin therapy in both primary and secondary prevention patients”

    Reviewin primary and secondary prevention

    Statin Prescribing in the Elderly: Special Considerations

    Current atherosclerosis reports

  10. Statins lower the risk of atherosclerotic cardiovascular disease in individuals with HIV.

    “these patients should be optimized with pharmacologic therapy to lower their cardiovascular risk through the addition of statin therapy to their regimen.”

    Reviewin individuals with HIV

    Recommendations for Managing Drug-Drug Interactions with Statins and HIV Medications

    American journal of cardiovascular drugs : drugs, devices, and other interventions

More on Statins

Low-density lipoprotein cholesterol

upin humans5upin reviews1HR 1.2–1.4

6 studies
  1. Low-density lipoprotein cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans (high LDL-C (LDL-C >=4.1 mmol/L) with lowest RC level vs controls) (HR, 1.20 [95% CI, 1.02-1.41]).

    “In contrast, in the high LDL-C group (LDL-C ≥4.1 mmol/L), even when RC was at the lowest level, ASCVD risk remained significantly higher than that of controls (HR, 1.20 [95% CI, 1.02-1.41]).”

    Humanshigh LDL-C (LDL-C >=4.1 mmol/L) with lowest RC level vs controls12.8 years

    Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk in Populations With Different Low-Density Lipoprotein Cholesterol Elevations: A Prospective Cohort Study

    Journal of the American Heart Association

  2. Low-density lipoprotein cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.40 (95% CI, 1.35 to 1.47)).

    “and for LDL-C of 1.40 (95%CI, 1.35-1.47).”

    Humans10 yearsn = 271,760

    Elevated levels of estimated low-density lipoprotein triglycerides is associated with risks for atherosclerotic cardiovascular disease and type 2 diabetes

    AHA Scientific Sessions 2025 abstract

  3. Low-density lipoprotein cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans.

    “All age groups showed positive associations between LDL-C and ASCVD risk, mostly with statistical significance from LDL-C of 160 mg/dL onward.”

    Humans

    Age-Related Associations of Low-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Cohort Study

    Journal of the American Heart Association

  4. Low-density lipoprotein cholesterol raises the risk of atherosclerotic cardiovascular disease.

    “low-density lipoprotein cholesterol and other apolipoprotein B-containing lipoproteins are causal drivers of atherosclerotic cardiovascular disease”

    Review

    Comparison of the 2025 ESC/EAS and 2026 ACC/AHA Guidelines for Dyslipidemia Management

    European journal of preventive cardiology

  5. Low-density lipoprotein cholesterol raises the risk of atherosclerotic cardiovascular disease in humans (familial hypercholesterolemia).

    “Familial hypercholesterolemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C), leading to a high risk of early onset atherosclerotic cardiovascular disease (ASCVD).”

    Reviewfamilial hypercholesterolemia

    Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association

    Journal of clinical lipidology

  6. Low-density lipoprotein cholesterol raises the risk of atherosclerotic cardiovascular disease in combination with other risk factors.

    “long-term exposure to the risk factor (LDL hypercholesterolemia), which, not adequately controlled and in combination with other risk factors, has favored the onset of major cardiovascular events.”

    Reviewin combination with other risk factors

    Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?

    Life (Basel, Switzerland)

More on Low-density lipoprotein cholesterol

Clonal hematopoiesis of indeterminate potential

upin humans5upin reviews1

6 studies
  1. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease in humans.

    “recognized as a potent risk factor for atherosclerotic cardiovascular disease”

    Review

    Clonal hematopoiesis of indeterminate potential and heart disease: What every internist needs to know

    Cleveland Clinic journal of medicine

  2. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease in humans.

    “it is also associated with an increased risk of nonmalignant diseases, such as atherosclerotic cardiovascular disease”

    Reviewblood

    Clonal Hematopoiesis and Its Impact on Human Health

    Annual review of medicine

  3. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease in humans.

    “The presence of these acquired mutations predisposes otherwise healthy adults to increased risk of several chronic aging-related conditions including hematologic cancers, atherosclerotic cardiovascular diseases, other inflammatory conditions, and mortality.”

    Review

    Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations

    Translational research : the journal of laboratory and clinical medicine

  4. Clonal hematopoiesis of indeterminate potential is associated with atherosclerotic cardiovascular disease in humans.

    “CHIP, common in elderly individuals, provides an opportunity understand and potentially modify age-related chronic inflammatory ASCVD risk.”

    Review

    Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease

    Current opinion in hematology

  5. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease.

    “as a new causal risk factor for atherosclerotic cardiovascular disease and heart failure”

    Review

    The role of clonal haematopoiesis in cardiovascular diseases: epidemiology and experimental studies

    Journal of internal medicine

  6. Clonal hematopoiesis of indeterminate potential raises the risk of atherosclerotic cardiovascular disease in humans (doubling of the risk).

    “CHIP is also associated with a doubling of the risk of atherosclerotic cardiovascular disease”

    Review

    Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease

    Nature reviews. Cardiology

More on Clonal hematopoiesis of indeterminate potential

Remnant cholesterol

upin humans4no changein humans1HR 1.03–2

5 studies
  1. Remnant cholesterol is associated with atherosclerotic cardiovascular disease in humans.

    “Compared with participants with concordantly low lipid levels, those with elevated non-HDL-C or RC but normal LDL-C had significantly higher ASCVD risk.”

    Humanschronic kidney disease; elevated remnant cholesterol but normal LDL cholesterol versus concordantly low lipid levelsmedian follow-up of 13.81 yearsn = 27,978

    Non-HDL cholesterol and remnant cholesterol are better indicators of atherosclerotic cardiovascular disease risk than LDL cholesterol in patients with chronic kidney disease

    Atherosclerosis

  2. Remnant cholesterol is associated with atherosclerotic cardiovascular disease in humans (HR, 1.03 [95% CI, 0.93-1.13]).

    “In the borderline-high LDL-C group (3.4 ≤ LDL-C < 4.1 mmol/L), those with the lowest RC levels showed no significant risk difference compared with controls (hazard ratio [HR], 1.03 [95% CI, 0.93-1.13])”

    Humansborderline-high LDL-C (3.4 <= LDL-C < 4.1 mmol/L) with lowest RC levels (<0.5 mmol/L) vs controls12.8 years

    Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk in Populations With Different Low-Density Lipoprotein Cholesterol Elevations: A Prospective Cohort Study

    Journal of the American Heart Association

  3. Remnant cholesterol is linked with a higher risk of atherosclerotic cardiovascular disease in humans (categorical RC Q4 vs Q1) (HR 2.00, 95% CI 1.22–3.27).

    “Atherosclerotic cardiovascular disease (HR Q4, 2.00; 95% CI 1.22–3.27; P-trend = 0.007)”

    Humanscategorical RC Q4 vs Q1

    The Remnant Cholesterol is associated with CVD incidence: A general population cohort study in Southwest China

    Research SquarePreprint

  4. Remnant cholesterol raises the risk of atherosclerotic cardiovascular disease in observational epidemiological and Mendelian randomization studies.

    “Elevated plasma concentration of remnant cholesterol, the cholesterol in triglyceride-rich lipoproteins, is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD)”

    Reviewin observational epidemiological and Mendelian randomization studies

    Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease

    Expert opinion on therapeutic targets

  5. Remnant cholesterol raises the risk of atherosclerotic cardiovascular disease in humans (residual lipid risk).

    “Remnant cholesterol, Lp(a), and LDL cholesterol represent three independent lipoprotein species causing ASCVD”

    Reviewresidual lipid risk

    Residual lipid risk in atherosclerotic cardiovascular disease

    European heart journal

More on Remnant cholesterol

C-reactive protein

upin humans4HR 1.02–2.17

4 studies
  1. C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (HR 1.36 (95% CI 1.30-1.43)).

    “the highest quintile of TyG, hs-CRP, and Lp(a) was associated with higher ASCVD risk, with hazard ratios (HRs) of 1.32 (95% CI 1.27-1.38), 1.36 (1.30-1.43), and 1.23 (1.19-1.27)”

    Humansn = 320,506

    Metabolic, inflammatory, and lipoprotein(a)-related risk profiling for incident ASCVD: a multi-biomarker study

    Frontiers in endocrinology

  2. C-reactive protein predicts atherosclerotic cardiovascular disease in humans.

    “small dense low-density lipoprotein cholesterol, hs-CRP, and education were also selected, whereas self-reported race was not.”

    Humans10 yearsn = 13,108

    Comprehensive Evaluation of Atherosclerotic Cardiovascular Disease Risk Predictors Across the Pooled Cohort Equations, Predicting Risk of Cardiovascular Disease Events, and an Expanded Model

    Journal of the American Heart Association

  3. C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (cumulative joint exposure G4 vs G1) (HR 2.17 (1.98, 2.37)).

    “compared with G1, G2, G3, and G4 had a higher risk of ASCVD HR (95% CI) were 1.45 (1.30, 1.62), 1.80 (1.66, 1.95), and 2.17 (1.98, 2.37), respectively.”

    Humanscumulative joint exposure G4 vs G1

    Temporal relationship between inflammation and metabolic disorders and its influence on atherosclerotic cardiovascular disease

    Frontiers in cardiovascular medicine

  4. C-reactive protein is associated with atherosclerotic cardiovascular disease in humans (HR 1.03 per 1.0 mg/L increase, 95% CI 1.02–1.05).

    “Joint modeling revealed a significant time-dependent association of hs-CRP trajectory with incident ASCVD (HR 1.03 per 1.0 mg/L increase, 95% CI 1.02–1.05, P < 0.001).”

    Humansper 1.0 mg/L increase

    Temporal Changes in High-Sensitivity C-Reactive Protein and Atherosclerotic Cardiovascular Disease in African Americans: The Jackson Heart Study

    AHA Scientific Sessions 2025 abstract

  5. C-reactive protein is linked with a higher risk of atherosclerotic cardiovascular disease in humans (adjusted HR 1.02, 95% CI 1.01–1.02).

    “Each unit increase in hs-CRP was associated with greater ASCVD risk (adjusted hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.01–1.02, P < 0.001).”

    Humansmedian 13.7 yearsn = 3,948

    Temporal Changes in High-Sensitivity C-Reactive Protein and Atherosclerotic Cardiovascular Disease in African Americans: The Jackson Heart Study

    AHA Scientific Sessions 2025 abstract

More on C-reactive protein

IL-6

upin humans4HR 1.48–1.54

4 studies
  1. IL-6 is associated with atherosclerotic cardiovascular disease in humans (IL-6 at or above cohort- and sex-specific medians; adjusted for CKM stage) (HR 1.48, 95% CI 1.33–1.64).

    “IL-6 at or above the median was associated with higher risks of atherosclerotic CVD (hazard ratio, 1.48; 95% CI, 1.33–1.64)”

    HumansIL-6 at or above cohort- and sex-specific medians; adjusted for CKM stagen = 9,894

    Inflammation and the Association of Early-stage Cardiovascular-Kidney-Metabolic Syndrome with Incident Cardiovascular Disease and All-cause Mortality: Findings from the CARDIA and MESA Cohorts

    American heart journal

  2. IL-6 is linked with a higher risk of atherosclerotic cardiovascular disease in humans after adjusting for LE8 metrics and demographics (HR 1.54 [1.05-2.25], p = 0.03).

    “Increased IL-6 was independently associated with ASCVD (HR 1.54 [1.05-2.25], p = 0.03)”

    Humansafter adjusting for LE8 metrics and demographics12 yearsn = 1,869

    Impact of life's essential eight and inflammatory markers on long-term cardiovascular disease risk and all-cause mortality: Insights from the Heart SCORE study

    Heart & lung : the journal of critical care

  3. Atherosclerotic cardiovascular disease is associated with IL-6 in humans.

    “Alteration of ECFC was associated with increased senescent phenotype and IL-6 levels.”

    Humans

    Functional Impairment of Endothelial Colony Forming Cells (ECFC) in Patients with Severe Atherosclerotic Cardiovascular Disease (ASCVD)

    International journal of molecular sciences

  4. IL-6 raises the risk of atherosclerotic cardiovascular disease in observational studies.

    “IL-6 has been identified as a source of residual risk for ASCVD”

    Reviewin observational studies

    The role of IL-6 in atherosclerosis: a narrative review

    Frontiers in cardiovascular medicine

More on IL-6

LDL-C

upin humans3downin humans1

4 studies
  1. LDL-C is linked with a higher risk of atherosclerotic cardiovascular disease in humans (sHR 1.69, 95% CI 1.35-2.12).

    “Elevated LDL-C by all equations was associated with ASCVD events (subdistribution hazards ratio [95% CI]: Martin-Hopkins, 1.69 [1.35-2.12]”

    Humans22.7 yearsn = 10,550

    Martin-Hopkins LDL equation best predicts cardiovascular risk

    Circulation. Population health and outcomes

  2. LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.

    “elevated low-density lipoprotein cholesterol (LDL-C) recognized as a causal factor and the primary target for the prevention of atherosclerotic cardiovascular disease (ASCVD)”

    Review

    Are we underestimating the benefits of lipid-lowering therapies?

    Pharmacological reviews

  3. LDL-C lowers the risk of atherosclerotic cardiovascular disease in randomised clinical trials.

    “Evidence from randomised clinical trials confirms that incremental LDL-C reductions lead to proportional reductions in cardiovascular events”

    Reviewin randomised clinical trials

    Upfront Combination or Stepwise Escalation: Personalising LDL-C Reduction in Clinical Practice

    Current atherosclerosis reports

  4. LDL-C raises the risk of atherosclerotic cardiovascular disease in humans.

    “Even younger individuals with a greater cumulative exposure to LDL-C, despite their age, may have a higher overall risk compared to older individuals with a lower cumulative exposure to LDL-C.”

    Review

    Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets

    American journal of preventive cardiology

More on LDL-C

Polygenic risk score

upin humans4OR 1.9

4 studies
  1. Polygenic risk score predicts atherosclerotic cardiovascular disease in humans (atherosclerotic cardiovascular disease) (4.9-fold higher incidence).

    “this reclassified subgroup had 4.9-fold higher incidence during the follow-up than those remaining low-risk.”

    Humansatherosclerotic cardiovascular disease

    Genetic scores add more predictive power at lower clinical risk

    medRxivPreprint

  2. Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (borderline PREVENT scores (5.0-7.5%)) (OR 1.9).

    “observed 10y ASCVD rate moved from 4.8% (4.0-5.7%) to 8.8% (7.7-10.0%) in low (bottom 20%) versus high (top 20%) PRS individuals, an odds ratio of 1.9”

    Humansborderline PREVENT scores (5.0-7.5%)

    Adding a polygenic risk score to the PREVENT clinical risk tool significantly improves cardiovascular risk prediction

    AHA Scientific Sessions 2025 abstract

  3. Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (highest tertile compared to lowest tertile) (RR 1.59, 95% CI 1.16–2.17).

    “The high-risk PRS increased ASCVD risk by 59% (Risk Ratio=1.59;95% Confidence Interval:1.16-2.17) in the highest tertile for AAs”

    Humanshighest tertile compared to lowest tertilen = 1,606

    Ancestry Specific Polygenic Risk Score, Dietary Patterns, Physical Activity, and Cardiovascular Disease

    medRxiv : the preprint server for health sciencesPreprint

  4. Polygenic risk score predicts atherosclerotic cardiovascular disease in European populations.

    “Polygenic risk scores (PRS), which quantify this inherited susceptibility, have demonstrated strong predictive performance in European populations, with accumulating evidence supporting their use in clinical practice.”

    Reviewin European populations

    Improving Polygenic Risk Prediction for Atherosclerotic Cardiovascular Disease in East Asian Populations

    JACC. Asia

More on Polygenic risk score

Curcumin

downin humans1

1 study
  1. Curcumin lowers the risk of atherosclerotic cardiovascular disease in humans with diabetes and atherosclerotic cardiovascular risk.

    “Upon assessing the (ASCVD) risk class distribution between the two groups, a significant difference was noted at the end of the trial (P = 0.004).”

    Human trialwith diabetes and atherosclerotic cardiovascular risk14 weeksn = 72

    Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk

    Scientific reports

More on Curcumin

All 290

Trial sponsors

Funding

21 grants since 2018

National Heart, Lung, and Blood Institute$17.7MGouvernement du Canada | Canadian Institutes of Health ResearchCA$130KUS Department of Veterans Affairs

Latest

Dec 2025: 27Jan 2026: 84Feb 2026: 119Mar 2026: 85Apr 2026: 14May 2026: 26Jun 2026: 31Jul 2026: 47Aug 2026: 111Sep 2026: 105Oct 2026: 222Nov 2026: 2191,090 papers in 12 months
Diabetes & Metabolic Syndrome

Higher urine ketone scores linked to lower artery disease risk

Compared with the lowest-scoring group, the highest-scoring group had 24% lower relative risk of artery disease in men and 22% in women.Compared with the lowest-scoring group, the highest-scoring group had 24% lower relative risk of artery disease in men and 22% in women.

Cohort studyBiomarkers
medRxiv

Genetic study finds no lower artery disease risk for immune target

Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.Heart artery disease odds were slightly higher, with an odds ratio of 1.06 per genetically predicted 19% decrease in a blood inflammation marker.

Preprint: Mendelian randomizationBlood and immune system
JACC Advances

Saturated fat’s cholesterol link may vary with genetic risk

An observational analysis of 20,940 Women’s Health Initiative participants linked saturated fat more strongly to LDL cholesterol at higher levels of inherited cholesterol…An observational analysis of 20,940 Women’s Health Initiative participants linked saturated fat more strongly to LDL cholesterol at higher levels of inherited cholesterol risk.

Cross-sectional · 20,940 peoplePopulations

See all 1,717 papers on atherosclerotic cardiovascular disease